Led · Series D · Aug 2026

Hadrian builds automated manufacturing facilities that mass-produce parts for vehicles used by the military. The company has opened multiple facilities, including a fourth site in Alabama announced in March to produce submarine parts. That Alabama facility was structured as a public/private partnership and valued at $2.4 billion, according to Hadrian. Hadrian has attracted large venture and institutional backers and recently raised a $1.37 billion round at a $7.87 billion valuation. About a year earlier it raised a $260 million Series C led by Founders Fund and Lux Capital, bringing total capital raised to roughly $2 billion per PitchBook estimates. The company's current plans and financing indicate continued expansion of its automated production footprint for defense supply chains.

Led · Equity · Aug 2026

SHINE Technologies develops a fusion-based approach to produce medical isotopes such as molybdenum-99, and also plans capability for iodine-131 and xenon-133. The company uses a liquid uranium target that is recycled, which it says reduces radioactive waste volume and operating costs compared with reactor-based production. SHINE has collaborated with U.S. national laboratories for more than 15 years and received technical support and funding from the DOE NNSA. Its commercial Chrysalis facility in Janesville, Wisconsin, is reported to be 75% complete and is positioned to be the world’s largest medical isotope production facility when operational. The recently announced conditional loan commitment from the DOE Office of Energy Dominance Financing is intended to help finish the project and enable market entry. Company leadership and government officials emphasize the project's role in onshoring Mo-99 supply, improving supply-chain reliability, and advancing nonproliferation objectives.

Participated · Series C · Jul 2026

Chai Discovery develops AI models that reason about biological structure and function to generate new molecular designs from scratch and put those models into a software platform used by pharma teams. The company reports partnerships and deployments with major pharmaceutical firms, including Eli Lilly and Pfizer. Its model lineup includes Chai-2, released in 2025 as the first zero-shot generative platform for fully de novo antibody design to achieve double-digit experimental success rates, and Chai-3, which materially improves target success rates and binding affinity versus its predecessor. Founded in 2024 and based in San Francisco, Chai aims to bring engineering precision, speed and scale to pre-clinical discovery. The company recently raised $400M in a Series C at a $3.8B valuation to accelerate R&D, deployment and partnerships.

Participated · Series H · Jun 2026

Airwallex offers an AI-native financial operating system and a suite of regulated financial infrastructure products, including payment acceptance, billing, global accounts, corporate cards, and spend management. The company holds 85+ licenses across North America, Europe, the Middle East, and Asia-Pacific and serves more than 676,000 businesses worldwide, directly or through platform partners. Airwallex reported $1.3 billion in annualized revenue and $287 billion in annualized transaction volume as of March 2026, with more than 90% of revenue coming from customers using multiple products. It is rolling out two new initiatives—T:0, an end-to-end AI-native finance platform currently in private beta, and Airi, a consumer wallet and agentic commerce infrastructure. The company plans to use recent funding to accelerate product development, expand its regulatory and infrastructure footprint, and scale teams to build next-generation AI-native financial software. Airwallex was founded in Melbourne in 2015 and is co-headquartered in San Francisco and Singapore, with over 2,300 employees across 27 offices.

Participated · Series H · May 2026

Anthropic is a premier artificial intelligence safety and research company renowned for developing Claude, a family of highly capable, steerable, and safe large language models. Founded by former OpenAI researchers, Anthropic pioneers techniques like "Constitutional AI" to build systems that are helpful, honest, and harmless. Beyond its core research, the company has rapidly scaled into a dominant market force, experiencing exponential revenue growth driven by widespread enterprise adoption. Anthropic has attracted unprecedented investor attention, recently raising approximately $30 billion at a $380 billion valuation, with ongoing negotiations potentially boosting its valuation to roughly $800 billion. As a leading competitor in the generative AI space, the company is reportedly exploring an IPO later this year.